tetano
Editor, Senior Moderator
J Allergy Clin Immunol Pract
. 2024 Mar 29:S2213-2198(24)00328-3.
doi: 10.1016/j.jaip.2024.03.035. Online ahead of print. Long-term impacts of COVID-19 on severe exacerbation and mortality in adult asthma: A nationwide population-based cohort study
Hyun Lee[SUP] 1 [/SUP], Bo-Guen Kim[SUP] 1 [/SUP], Cho Yun Jeong[SUP] 2 [/SUP], Dong Won Park[SUP] 1 [/SUP], Tai Sun Park[SUP] 1 [/SUP], Ji-Yong Moon[SUP] 1 [/SUP], Tae-Hyung Kim[SUP] 1 [/SUP], Jang Won Sohn[SUP] 1 [/SUP], Ho Joo Yoon[SUP] 1 [/SUP], Jong Seung Kim[SUP] 3 [/SUP], Sang-Heon Kim[SUP] 4 [/SUP]
Affiliations
Background: In adults with asthma, the long-term impact of previous coronavirus disease 2019 (COVID-19) on severe exacerbations and mortality is unclear.
Objective: We evaluated the long-term risk of severe exacerbation and mortality in adults with asthma who recovered from COVID-19.
Methods: Using the Korean National Health Insurance claim-based database, we compared the risk of severe exacerbations (emergency room visits or hospitalization) and mortality in adults with asthma aged >20 years recovered from COVID-19 between October 8, 2020, and December 16, 2021 (COVID-19 cohort, n=10,739) with 1:1 propensity score-matched controls (n=10,739).
Results: During a median follow-up of 87 (range, 15-448) days, the incidence rate of severe exacerbation in the COVID-19 cohort and matched cohort was 187.3 and 119.3 per 10,000 person-years, respectively. The COVID-19 cohort had a higher risk of severe exacerbation compared to the matched cohort (hazard ratio=1.57; 95% confidence interval [CI]=1.06-2.32). During a median follow-up of 360 (range, 15-721) days, the incidence rate of death in the COVID-19 and matched cohort was 128.3 and 73.5 per 10,000 person-years, respectively. The COVID-19 cohort had a higher risk of death (hazard ratio=1.76; 95% CI=1.33-2.30) compared to the matched cohort. When further analyzed by COVID-19 severity, severe COVID-19 was associated with a 5.12-fold (95% CI=3.27-8.01) and 7.31-fold (95% CI=5.41-9.88) increased risk of severe exacerbation and death, respectively, but non-severe COVID-19 was not.
Conclusion: Our study heightens that severe COVID-19 is associated with increased long-term risk of severe exacerbation and mortality among individuals with asthma.
Keywords: COVID-19; asthma; exacerbation; mortality.
. 2024 Mar 29:S2213-2198(24)00328-3.
doi: 10.1016/j.jaip.2024.03.035. Online ahead of print. Long-term impacts of COVID-19 on severe exacerbation and mortality in adult asthma: A nationwide population-based cohort study
Hyun Lee[SUP] 1 [/SUP], Bo-Guen Kim[SUP] 1 [/SUP], Cho Yun Jeong[SUP] 2 [/SUP], Dong Won Park[SUP] 1 [/SUP], Tai Sun Park[SUP] 1 [/SUP], Ji-Yong Moon[SUP] 1 [/SUP], Tae-Hyung Kim[SUP] 1 [/SUP], Jang Won Sohn[SUP] 1 [/SUP], Ho Joo Yoon[SUP] 1 [/SUP], Jong Seung Kim[SUP] 3 [/SUP], Sang-Heon Kim[SUP] 4 [/SUP]
Affiliations
- PMID: 38556045
- DOI: 10.1016/j.jaip.2024.03.035
Background: In adults with asthma, the long-term impact of previous coronavirus disease 2019 (COVID-19) on severe exacerbations and mortality is unclear.
Objective: We evaluated the long-term risk of severe exacerbation and mortality in adults with asthma who recovered from COVID-19.
Methods: Using the Korean National Health Insurance claim-based database, we compared the risk of severe exacerbations (emergency room visits or hospitalization) and mortality in adults with asthma aged >20 years recovered from COVID-19 between October 8, 2020, and December 16, 2021 (COVID-19 cohort, n=10,739) with 1:1 propensity score-matched controls (n=10,739).
Results: During a median follow-up of 87 (range, 15-448) days, the incidence rate of severe exacerbation in the COVID-19 cohort and matched cohort was 187.3 and 119.3 per 10,000 person-years, respectively. The COVID-19 cohort had a higher risk of severe exacerbation compared to the matched cohort (hazard ratio=1.57; 95% confidence interval [CI]=1.06-2.32). During a median follow-up of 360 (range, 15-721) days, the incidence rate of death in the COVID-19 and matched cohort was 128.3 and 73.5 per 10,000 person-years, respectively. The COVID-19 cohort had a higher risk of death (hazard ratio=1.76; 95% CI=1.33-2.30) compared to the matched cohort. When further analyzed by COVID-19 severity, severe COVID-19 was associated with a 5.12-fold (95% CI=3.27-8.01) and 7.31-fold (95% CI=5.41-9.88) increased risk of severe exacerbation and death, respectively, but non-severe COVID-19 was not.
Conclusion: Our study heightens that severe COVID-19 is associated with increased long-term risk of severe exacerbation and mortality among individuals with asthma.
Keywords: COVID-19; asthma; exacerbation; mortality.